Compare TW & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TW | UTHR |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7B | 23.9B |
| IPO Year | 2019 | 1999 |
| Metric | TW | UTHR |
|---|---|---|
| Price | $130.11 | $591.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | $131.93 | ★ $687.14 |
| AVG Volume (30 Days) | ★ 1.6M | 503.7K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 62.23 | 13.07 |
| EPS | 2.75 | ★ 18.80 |
| Revenue | $892,659,000.00 | ★ $1,483,300,000.00 |
| Revenue This Year | $15.15 | $2.07 |
| Revenue Next Year | $13.36 | $10.89 |
| P/E Ratio | $46.70 | ★ $30.80 |
| Revenue Growth | ★ 15.10 | 2.38 |
| 52 Week Low | $91.42 | $452.44 |
| 52 Week High | $128.97 | $614.23 |
| Indicator | TW | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 80.03 | 58.56 |
| Support Level | $95.14 | $525.83 |
| Resistance Level | N/A | $608.62 |
| Average True Range (ATR) | 3.19 | 18.00 |
| MACD | 0.41 | -2.70 |
| Stochastic Oscillator | 96.83 | 58.53 |
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.